TY - JOUR
T1 - Association between aspirin use during pregnancy and cardiovascular risk factors 2–7 years after delivery
T2 - The nuMoM2b Heart Health Study
AU - Theilen, Lauren H.
AU - Greenland, Philip
AU - Varagic, Jasmina
AU - Catov, Janet
AU - Shanks, Anthony
AU - Thorsten, Vanessa
AU - Parker, Corette B.
AU - McNeil, Rebecca
AU - Mercer, Brian
AU - Hoffman, Matthew
AU - Wapner, Ronald
AU - Haas, David
AU - Simhan, Hyagriv
AU - Grobman, William
AU - Chung, Judith H.
AU - Levine, Lisa D.
AU - Barnes, Shannon
AU - Bairey Merz, Noel
AU - Saade, George
AU - Silver, Robert M.
N1 - Funding Information:
This work was supported by cooperative agreement funding from the National Heart, Lung, and Blood Institute and the Eunice Kennedy Shriver National Institute of Child Health and Human Development: U10‐HL119991; U10‐HL119989; U10‐HL120034; U10‐HL119990; U10‐HL120006; U10‐HL119992; U10‐HL120019; U10‐HL119993; U10‐HL120018, and U01HL145358. The study was also supported by grant funding from the Eunice Kennedy Shriver National Institute of Child Health and Human Development: U10 HD063036; U10 HD063072; U10 HD063047; U10 HD063037; U10 HD063041; U10 HD063020; U10 HD063046; U10 HD063048; and U10 HD063053. Support was also provided by the National Institutes of Health: Office of Research on Women's Health through U10‐HL119991; Office of Behavioral and Social Sciences Research through U10‐HL119991 and U10‐HL119992; and the National Center for Advancing Translational Sciences through UL‐1‐TR000124, UL‐1‐TR000153, UL‐1‐TR000439, and UL‐1‐TR001108; and the Barbra Streisand Women’s Cardiovascular Research and Education Program, and the Erika J. Glazer Women’s Heart Research Initiative, Cedars-Sinai Medical Center, Los Angeles.
Publisher Copyright:
© 2022 International Society for the Study of Hypertension in Pregnancy
PY - 2022/6
Y1 - 2022/6
N2 - Objectives: To evaluate the association between aspirin use during first pregnancy and later maternal cardiovascular risk. Study design: In this secondary analysis of a prospective cohort, we included participants who carried their first pregnancy to 20 + weeks, had data regarding aspirin use, and attended a study visit 2–7 years following delivery. The exposure was aspirin use during the first pregnancy. We calculated aspirin use propensity scores from logistic regression models including baseline variables associated with aspirin use in pregnancy and cardiovascular risk. Outcomes of interest were incident cardiovascular-related diagnoses 2–7 years following delivery. Robust Poisson regression calculated the risk of outcomes by aspirin exposure, adjusting for the aspirin use propensity score. Main outcome measures: The primary outcome was a composite of incident cardiovascular diagnoses at the time of the study visit: cardiovascular events, chronic hypertension, metabolic syndrome, prediabetes or type 2 diabetes, dyslipidemia, and chronic kidney disease. Results: Of 4,480 women included, 84 (1.9%) reported taking aspirin during their first pregnancy. 52.6% of participants in the aspirin-exposed group and 43.0% in the unexposed group had the primary outcome. After adjusting for the aspirin use propensity scores, aspirin use during the first pregnancy was not associated with any of the outcomes. Conclusion: We did not detect an association between aspirin use during the first pregnancy and cardiovascular-related diagnoses 2–7 years later. Our study was only powered to detect a large difference in relative risk, so we cannot rule out a smaller difference that may be clinically meaningful.
AB - Objectives: To evaluate the association between aspirin use during first pregnancy and later maternal cardiovascular risk. Study design: In this secondary analysis of a prospective cohort, we included participants who carried their first pregnancy to 20 + weeks, had data regarding aspirin use, and attended a study visit 2–7 years following delivery. The exposure was aspirin use during the first pregnancy. We calculated aspirin use propensity scores from logistic regression models including baseline variables associated with aspirin use in pregnancy and cardiovascular risk. Outcomes of interest were incident cardiovascular-related diagnoses 2–7 years following delivery. Robust Poisson regression calculated the risk of outcomes by aspirin exposure, adjusting for the aspirin use propensity score. Main outcome measures: The primary outcome was a composite of incident cardiovascular diagnoses at the time of the study visit: cardiovascular events, chronic hypertension, metabolic syndrome, prediabetes or type 2 diabetes, dyslipidemia, and chronic kidney disease. Results: Of 4,480 women included, 84 (1.9%) reported taking aspirin during their first pregnancy. 52.6% of participants in the aspirin-exposed group and 43.0% in the unexposed group had the primary outcome. After adjusting for the aspirin use propensity scores, aspirin use during the first pregnancy was not associated with any of the outcomes. Conclusion: We did not detect an association between aspirin use during the first pregnancy and cardiovascular-related diagnoses 2–7 years later. Our study was only powered to detect a large difference in relative risk, so we cannot rule out a smaller difference that may be clinically meaningful.
KW - Adverse pregnancy outcomes
KW - Cardiovascular prevention
KW - Maternal health
KW - Pregnancy as a window to future health
KW - Pregnancy complications
UR - http://www.scopus.com/inward/record.url?scp=85124386817&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85124386817&partnerID=8YFLogxK
U2 - 10.1016/j.preghy.2022.01.012
DO - 10.1016/j.preghy.2022.01.012
M3 - Article
C2 - 35158155
AN - SCOPUS:85124386817
SN - 2210-7789
VL - 28
SP - 28
EP - 34
JO - Pregnancy Hypertension
JF - Pregnancy Hypertension
ER -
